Top

Published in:

01-03-2010 | Original Paper

Dietary Supplementation with S-Adenosyl Methionine Delays the Onset of Motor Neuron Pathology in a Murine Model of Amyotrophic Lateral Sclerosis

Authors: James Suchy, Sangmook Lee, Ambar Ahmed, Thomas B. Shea

Published in: NeuroMolecular Medicine | Issue 1/2010

Abstract

The full range of causative factors in Amyotrophic lateral sclerosis (ALS) remains elusive, but oxidative stress is recognized as a contributing factor. Mutations in Cu/Zn superoxide dismutase 1 (SOD-1), associated with familial ALS, promote widespread oxidative damage. Mice-expressing G93A mutant human SOD-1 mice display multiple pathological changes characteristic of ALS and are therefore useful for therapeutic development. Dietary supplementation with S-adenosyl methionine (SAM) has provided multiple neuroprotective effects in mouse models of age-related cognitive pathology. We examined herein whether SAM supplementation could affect the course of motor neuron pathology in mice-expressing mutant human SOD-1. SAM delayed disease onset by 2–3 weeks. SAM also delayed hallmarks of neurodegeneration in these mice and in ALS, including preventing loss of motor neurons, and reducing gliosis, SOD-1 aggregation, protein carbonylation, and induction of antioxidant activity. SAM did not increase survival time. These preliminary findings, using a single concentration of SAM, suggest that SAM supplementation maybe useful as part of a comprehensive therapeutic approach for ALS.

Agar, J., & Durham, H. (2003). Relevance of oxidative injury in the pathogenesis of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord, 4, 232–242.CrossRefPubMed

Barbeito, L. H., Pehar, M., Cassina, P., Vargas, M. R., Peluffo, H., Viera, L., et al. (2004). A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Research Brain Research Reviews, 47, 263–274.CrossRefPubMed

Barber, S. C., Mead, R. J., & Shaw, P. J. (2006). Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochimica et Biophysica Acta, 1762, 1051–1067.PubMed

Barneoud, P., & Curet, O. (1999). Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Experimental Neurology, 155, 243–251.CrossRefPubMed

Barneoud, P., Lolivier, J., Sanger, D. J., Scatton, B., & Moser, P. (1997). Quantitative motor assessment in FALS mice: A longitudinal study. NeuroReport, 8, 2861–2865.PubMedCrossRef

Bottiglieri, T. (2002). S-Adenosyl-L-methionine (SAMe): From the bench to the bedside–molecular basis of a pleiotropic molecule. American Journal of Clinical Nutrition, 76, 1151S–1157S.PubMed

Bottiglieri, T., Godfrey, P., Flynn, T., Carney, M. W., Toone, B. K., & Reynolds, E. H. (1990). Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. Journal of Neurology, Neurosurgery and Psychiatry, 53, 1096–1098.CrossRef

Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annual Review of Neuroscience, 27, 723–749.CrossRefPubMed

Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., & Shea, T. B. (2008a). Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: A 1-year, open-label pilot study with an 16-month caregiver extension. American Journal of Alzheimer’s Disease and Other Dementias, 23, 571–585.CrossRefPubMed

Chan, A., & Shea, T. B. (2007). Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Medicine, 9, 264–269.CrossRefPubMed

Chan, A., Tchantchou, F., Graves, V., Rozen, R., & Shea, T. B. (2008b). Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: Critical role of S-adenosyl methionine. The Journal of Nutrition, Health and Aging, 12, 252–261.CrossRef

Chi, L., Ke, Y., Luo, C., Gozal, D., & Liu, R. (2007). Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience, 144, 991–1003.CrossRefPubMed

Chiang, P. K., Gordon, R. K., Tal, J., Zeng, G. C., Doctor, B. P., Pardhasaradhi, K., et al. (1996). S-Adenosylmethionine and methylation. FASEB Journal, 10, 471–480.PubMed

Cozzolino, M., Ferri, A., & Carri, M. T. (2008). Amyotrophic lateral sclerosis: From current developments in the laboratory to clinical implications. Antioxidants and Redox Signaling, 10, 405–443.CrossRefPubMed

Dupuis, L., Gonzalez de Aguilar, J. L., Oudart, H., de Tapia, M., Barbeito, L., & Loeffler, J. P. (2004). Mitochondria in amyotrophic lateral sclerosis: A trigger and a target. Neuro-Degenerative Diseases, 1, 245–254.PubMed

Dwyer, B. E., Lu, S. Y., & Nishimura, R. N. (1998). Heme oxygenase in the experimental ALS mouse. Experimental Neurology, 150, 206–212.CrossRefPubMed

Erdmann, K., Cheung, B. W., Immenschuh, S., & Schroder, H. (2008). Heme oxygenase-1 is a novel target and antioxidant mediator of S-adenosylmethionine. Biochemical and Biophysical Research Communications, 368, 937–941.CrossRefPubMed

Esposito, E., Rossi, C., Amodio, R., Di Castelnuovo, A., Bendotti, C., Rotondo, T., et al. (2000). Lyophilized red wine administration prolongs survival in an animal model of amyotrophic lateral sclerosis. Annals of Neurology, 48, 686–687.CrossRefPubMed

Exner, M., Minar, E., Wagner, O., & Schillinger, M. (2004). The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radical Biology and Medicine, 37, 1097–1104.CrossRefPubMed

Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, M. L., et al. (2008). Lithium delays progression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 105, 2052–2057.CrossRefPubMed

Fujita, K., Kato, T., Yamauchi, M., Ando, M., Honda, M., & Nagata, Y. (1998). Increases in fragmented glial fibrillary acidic protein levels in the spinal cords of patients with amyotrophic lateral sclerosis. Neurochemical Research, 23, 169–174.CrossRefPubMed

Gharib, A., Sarda, N., Chabannes, B., Cronenberger, L., & Pacheco, H. (1982). The regional concentrations of S-adenosyl-L-methionine, S-adenosyl-L-homocysteine, and adenosine in rat brain. Journal of Neurochemistry, 38, 810–815.CrossRefPubMed

Grunfeld, J. F., Barhum, Y., Blondheim, N., Rabey, J. M., Melamed, E., & Offen, D. (2007). Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Experimental Neurology, 204, 260–263.CrossRefPubMed

Guo, H., Lai, L., Butchbach, M. E., Stockinger, M. P., Shan, X., Bishop, G. A., et al. (2003). Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Human Molecular Genetics, 12, 2519–2532.CrossRefPubMed

Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., et al. (1996). Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology, 39, 147–157.CrossRefPubMed

Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., et al. (1994). Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 264, 1772–1775.CrossRefPubMed

Hensley, K., Mhatre, M., Mou, S., Pye, Q. N., Stewart, C., West, M., et al. (2006). On the relation of oxidative stress to neuroinflammation: Lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxidants and Redox Signaling, 8, 2075–2087.CrossRefPubMed

Ho, P. I., Ashline, D., Dhitavat, S., Ortiz, D., Collins, S. C., Shea, T. B., et al. (2003). Folate deprivation induces neurodegeneration: Roles of oxidative stress and increased homocysteine. Neurobiology of Diseases, 14, 32–42.CrossRef

Ho, P. I., Ortiz, D., Rogers, E., & Shea, T. B. (2002). Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. Journal of Neuroscience Research, 70, 694–702.CrossRefPubMed

Holzbaur, E. L., Howland, D. S., Weber, N., Wallace, K., She, Y., Kwak, S., et al. (2006). Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiology of Diseases, 23, 697–707.CrossRef

Hyland, K., Smith, I., Bottiglieri, T., Perry, J., Wendel, U., Clayton, P. T., et al. (1988). Demyelination and decreased S-adenosylmethionine in 5, 10-methylenetetrahydrofolate reductase deficiency. Neurology, 38, 459–462.PubMed

Ito, H., Wate, R., Zhang, J., Ohnishi, S., Kaneko, S., Ito, H., et al. (2008). Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Experimental Neurology, 213, 448–455.CrossRefPubMed

Izumi, Y., & Kaji, R. (2007). Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve, 59, 1141–1147.PubMed

Johnston, J. A., Dalton, M. J., Gurney, M. E., & Kopito, R. R. (2000). Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 97, 12571–12576.CrossRefPubMed

Julien, J. P., & Mushynski, W. E. (1998). Neurofilaments in health and disease. Progress in Nucleic Acid Research and Molecular Biology, 61, 1–23.CrossRefPubMed

Jung, C., Rong, Y., Doctrow, S., Baudry, M., Malfroy, B., & Xu, Z. (2001). Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neuroscience Letters, 304, 157–160.CrossRefPubMed

Kennedy, B. P., Bottiglieri, T., Arning, E., Ziegler, M. G., Hansen, L. A., & Masliah, E. (2004). Elevated S-adenosylhomocysteine in Alzheimer brain: Influence on methyltransferases and cognitive function. Journal of neural transmission, 111, 547–567.CrossRefPubMed

Levine, J. B., Kong, J., Nadler, M., & Xu, Z. (1999). Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia, 28, 215–224.CrossRefPubMed

Lieber, C. S., & Packer, L. (2002). S-Adenosylmethionine: molecular, biological, and clinical aspects–an introduction. American Journal of Clinical Nutrition, 76, 1148S–1150S.PubMed

Liu, R., Li, B., Flanagan, S. W., Oberley, L. W., Gozal, D., & Qiu, M. (2002). Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1-mediated motor neuron cell death and increase amyotrophic lateral sclerosis-like transgenic mouse survival. Journal of Neurochemistry, 80, 488–500.CrossRefPubMed

Lu, S. C. (2000). S-Adenosylmethionine. International Journal of Biochemistry and Cell Biology, 32, 391–395.CrossRefPubMed

Mahoney, D. J., Kaczor, J. J., Bourgeois, J., Yasuda, N., & Tarnopolsky, M. A. (2006). Oxidative stress and antioxidant enzyme upregulation in SOD1–G93A mouse skeletal muscle. Muscle and Nerve, 33, 809–816.CrossRefPubMed

Mattson, M. P., & Shea, T. B. (2003). Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neurosciences, 26, 137–146.CrossRefPubMed

Muller, T., Woitalla, D., Hauptmann, B., Fowler, B., & Kuhn, W. (2001). Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson’s disease. Neuroscience Letters, 308, 54–56.CrossRefPubMed

Oommen, A. M., Griffin, J. B., Sarath, G., & Zempleni, J. (2005). Roles for nutrients in epigenetic events. The Journal of Nutritional Biochemistry, 16, 74–77.CrossRefPubMed

Park, J. H., Hong, Y. H., Kim, H. J., Kim, S. M., Kim, M. J., Park, K. S., et al. (2007). Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model. Neuroscience Letters, 413, 265–269.CrossRefPubMed

Perluigi, M., Poon, H. F., Maragos, W., Pierce, W. M., Klein, J. B., Calabrese, V., et al. (2005). Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol Cell Proteomics, 4, 1849–1861.CrossRefPubMed

Poon, H. F., Hensley, K., Thongboonkerd, V., Merchant, M. L., Lynn, B. C., Pierce, W. M., et al. (2005). Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice–a model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 39, 453–462.CrossRefPubMed

Rakhit, R., Crow, J. P., Lepock, J. R., Kondejewski, L. H., Cashman, N. R., & Chakrabartty, A. (2004). Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. Journal of Biological Chemistry, 279, 15499–15504.CrossRefPubMed

Rao, S. D., & Weiss, J. H. (2004). Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends in Neurosciences, 27, 17–23.CrossRefPubMed

Ratter, F., Germer, M., Fischbach, T., Schulze-Osthoff, K., Peter, M. E., Droge, W., et al. (1996). S-adenosylhomocysteine as a physiological modulator of Apo-1-mediated apoptosis. International Immunology, 8, 1139–1147.CrossRefPubMed

Remington, R., Chan, A., Paskavitz, J., & Shea, T. B. (2009). Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: A placebo-controlled pilot study. American Journal of Alzheimer’s Disease and Other Dementias, 24, 27–33.CrossRefPubMed

Robberecht, W. (2000). Oxidative stress in amyotrophic lateral sclerosis. Journal of Neurology, 247(Suppl 1), I1–I6.CrossRefPubMed

Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59–62.CrossRefPubMed

Rothstein, J. D. (1996). Therapeutic horizons for amyotrophic lateral sclerosis. Current Opinion in Neurobiology, 6, 679–687.CrossRefPubMed

Schatz, R. A., Wilens, T. E., & Sellinger, O. Z. (1981). Decreased in vivo protein and phospholipid methylation after in vivo elevation of brain S-adenosyl-homocysteine. Biochemical and Biophysical Research Communications, 98, 1097–1107.CrossRefPubMed

Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis, 9, 4–15.CrossRefPubMed

Sekiya, M., Ichiyanagi, T., Ikeshiro, Y., & Yokozawa, T. (2009). The Chinese prescription Wen-Pi-Tang extract delays disease onset in amyotrophic lateral sclerosis model mice while attenuating the activation of glial cells in the spinal cord. Biological and Pharmaceutical Bulletin, 32, 382–388.CrossRefPubMed

Selhub, J., & Miller, J. W. (1992). The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. American Journal of Clinical Nutrition, 55, 131–138.PubMed

Shea, T. B., & Chan, A. (2008). S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer’s disease. Journal of Alzheimer’s Disease, 13, 67–70.PubMed

Shea, T. B., & Rogers, E. (2002). Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: Augmentation by vitamin E. Molecular Brain Research, 108, 1–6.CrossRefPubMed

Shibata, N. (2001). Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology, 21, 82–92.CrossRefPubMed

Strong, M. J. (2003). The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacology and Therapeutics, 98, 379–414.CrossRefPubMed

Tchantchou, F., Graves, M., Falcone, D., & Shea, T. B. (2008). S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: Implications for S-adenosyl methionine as a neuroprotective dietary supplement. Journal of Alzheimer’s Disease, 14, 323–328.PubMed

Tchantchou, F., Graves, M., & Shea, T. B. (2006). Expression and activity of methionine cycle genes are altered following folate and vitamin E deficiency under oxidative challenge: Modulation by apolipoprotein E-deficiency. Nutritional Neuroscience, 9, 17–24.CrossRefPubMed

Turner, B. J., & Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Progress in Neurobiology, 85, 94–134.CrossRefPubMed

Veldink, J. H., Kalmijn, S., Groeneveld, G. J., Wunderink, W., Koster, A., de Vries, J. H., et al. (2007). Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 78, 367–371.CrossRef

Wang, R., & Zhang, D. (2005). Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. European Journal of Neuroscience, 22, 2376–2380.CrossRefPubMed

Watanabe, M., Dykes-Hoberg, M., Culotta, V. C., Price, D. L., Wong, P. C., & Rothstein, J. D. (2001). Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Diseases, 8, 933–941.CrossRef

Weydt, P., Hong, S. Y., Kliot, M., & Moller, T. (2003). Assessing disease onset and progression in the SOD1 mouse model of ALS. NeuroReport, 14, 1051–1054.CrossRefPubMed

Weydt, P., Hong, S., Witting, A., Moller, T., Stella, N., & Kliot, M. (2005). Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6, 182–184.CrossRefPubMed

Xu, Z., Chen, S., Li, X., Luo, G., Li, L., & Le, W. (2006). Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochemical Research, 31, 1263–1269.CrossRefPubMed

Zhang, X., Chen, S., Li, L., Wang, Q., & Le, W. (2008). Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology, 54, 1112–1119.CrossRefPubMed

Title: Dietary Supplementation with S-Adenosyl Methionine Delays the Onset of Motor Neuron Pathology in a Murine Model of Amyotrophic Lateral Sclerosis
Authors: James Suchy
Sangmook Lee
Ambar Ahmed
Thomas B. Shea
Publication date: 01-03-2010
Publisher: Humana Press Inc
Published in: NeuroMolecular Medicine / Issue 1/2010
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-009-8089-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dietary Supplementation with S-Adenosyl Methionine Delays the Onset of Motor Neuron Pathology in a Murine Model of Amyotrophic Lateral Sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Alzheimer’s Disease and Neuronal Network Activity

Functional Alterations in Memory Networks in Early Alzheimer’s Disease

Synaptic Depression and Aberrant Excitatory Network Activity in Alzheimer’s Disease: Two Faces of the Same Coin?

Epileptic Seizures in AD Patients

Translin-Associated Factor X Gene (TSNAX) may be Associated with Female major Depressive Disorder in the Japanese Population

Adverse Stress, Hippocampal Networks, and Alzheimer’s Disease